

Evaluate the Remission MAINTenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.

NCT03290456

Status	RECRUITING
Phase	Not Applicable
Sponsor	Hospices Civils de Lyon
Enrollment	146 participants

Key Eligibility Criteria

Inclusion (7)

- Patients with a diagnosis of MPA or GPA independently of ANCA status,
- Patient aged of 18 years or older,
- Patients with newly-diagnosed disease or relapsing disease at the time of screening, with an inactive disease defined as a BVAS = 0,
- Patients receiving maintenance infusion of rituximab 500 mg at 6 and 12 months after the start of vasculitis induction
- Patients receiving 5-10 mg/day of prednisone at screening,
- ... and 2 more (see full listing online)

Exclusion (13)

- Patients with EGPA, or other vasculitides, defined by the ACR criteria and/or the Chapel Hill Consensus Conference,
- Patients with vasculitis with active disease defined as a BVAS ≥ 1 ,
- Patients with acute infections or chronic active infections (including HIV, HBV or HCV),
- Patients with active cancer or recent cancer (≤ 5 years), except basocellular carcinoma and prostatic cancer of low activity controlled by hormonal treatment,
- Pregnant women and lactation. Patients with childbearing potential should have reliable contraception for the all duration of the study,
- ... and 8 more (see full listing online)

Locations (45 total)

CHU Amiens-Hôpital Nord, Amiens, France
CHU Angers, Angers, France
Clinique Rhône-Durance, Avignon, France
... and 42 more locations

<https://clinicaltrials.gov/study/NCT03290456>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.